gloup original aqua 84%, powder a / carrageenan maltodextrin 4%, sucrose 10%, citric acid 0.5%, potassium sorbate 0.80%, calcium chloride 94% 0.1%, natural flavor 0.2%, carmine 50% 0.15% gel
golden tree medicines belgium - 500ml plastic bottle - gel - aqua 84%, powder a / carrageenan maltodextrin 4%, sucrose 10%, citric acid 0.5%, potassium sorbate 0.80%, calcium chloride 94% 0.1%, natural flavor 0.2%, carmine 50% 0.15% - medical devices-medical devices
hextril 0,1 % mouthwash
johnson & johnson consumer sa-nv - hexetidine 0,1 g/100 ml - mouthwash - 0,1 % - hexetidine 1 mg/ml - hexetidine
hextril spray 0,20 % oromucos. spray sol.
johnson & johnson consumer sa-nv - hexetidine 0,2 g/100 ml - oromucosal spray, solution - 0,20 % - hexetidine 2 mg/ml - hexetidine
hextril 0,1 % mouthwash
johnson & johnson consumer sa-nv - hexetidine 0,1 g/100 ml - mouthwash - hexetidine
dextil 50ml/100ml syr
dolphin - dextromethorphan hbr,guaiphenesin,chlorpheniramine maleate,phenylpropanolamine hcl. - syr - 7.5,100,2,5;mg/5ml - 50ml/100ml
dextrim syrup
beximco pharmaceuticals ltd. - dextromethorphan hydrobromide + phenylephrine hydrochloride + triprolidine hydrochloride - syrup - 400 mg + 200 mg + 50 mg/100 ml
kryptade
agrihealth nz limited - potassium citrate; sodium chloride; sodium bicarbonate; glycine; beta-cyclodextrin; glucose monohydrate; arginine; potassium phosphate monobasic; malto-dextrine; potassium chloride - potassium citrate 1.2 g/kg; sodium chloride 77.5 g/kg; sodium bicarbonate 57.5 g/kg; glycine 76.8 g/kg; beta-cyclodextrin 125 g/kg; glucose monohydrate 500 g/kg; arginine 3.2 g/kg; potassium phosphate monobasic 25 g/kg; malto-dextrine 120.8 g/kg; potassium chloride 8.8 g/kg - oral nutrient/electrolyte
candril sachets soluble tablet
g.d.searle, united kingdom - maltodextrin,aspartame - soluble tablet - 97,3 g,
candril sachets soluble tablet
g.d.searle, united kingdom - maltodextrin,aspartame - soluble tablet - 97,3 g,
kyprolis
amgen europe b.v. - carfilzomib - multiple myeloma - antineoplastic agents - kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.